

# Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria

Gunnel Lundin, Jamileh Hashemi, Ylva Floderus, Stig Thunell, Erling Sagen, Astrid Lægred, Wassif Wassif, Timothy Peters, Maria Anvret

## Abstract

We have detected four different mutations in the porphobilinogen deaminase (PBGD) gene in acute intermittent porphyria (AIP) families from England, Norway, and Sweden. A splicing mutation in the first position of intron 8 (Int8+1) was found in a family from England and a missense mutation in exon 12 (Glu<sup>250</sup>) was detected in a Norwegian family. Two mutations were identified in Swedish families, one splicing mutation in the first position of intron 3 (Int3+1) and one missense mutation in exon 8 (Pro<sup>119</sup>).

(J Med Genet 1995;32:979-981)

Fifty-nine mutations have been published in the porphobilinogen deaminase (PBGD: hydroxymethylbilane synthase, EC 4.3.1.8) gene associated with the autosomal dominant disease acute intermittent porphyria (AIP).<sup>1-10</sup> PBGD is the third enzyme involved in haem synthesis, and AIP patients have a partial deficiency of the enzyme activity. When the demand for haem is increased, for example by alcohol or drug usage, the precursors ALA ( $\delta$ -aminolaevulinic acid) and PBG (porphobilinogen) accumulate in tissues and are probably responsible for the toxic effects in the neuropsychiatric porphyrias. AIP seldom presents before puberty, many carriers are asymptomatic, and the disease can often be difficult to diagnose. The symptoms are varied with sometimes severe attacks of abdominal pain, paralysis, mental disturbances, and autonomic dysfunction.<sup>11</sup>

The PBGD gene spans over 10 kb and comprises 15 exons. Mutations have been reported

in all regions of the gene except in exons 2 and 11. The hot spots for mutations are exons 10 and 12. In Swedish families, six mutations have been found previously, one in exon 8 (Arg<sup>116</sup>), four in exon 10 (Arg<sup>167</sup>, Arg<sup>173</sup>, Trp<sup>198</sup>, and Arg<sup>201</sup>), and one, a splicing mutation, at the border of intron 9 and exon 10.<sup>11213</sup> The mutation affecting Trp<sup>198</sup> in exon 10 originates from Arjeplog in northern Sweden and is the most common mutation among Swedish AIP patients.<sup>12</sup>

## Materials and methods

### PATIENTS

Genomic DNA from one Norwegian, one English, and two Swedish AIP families were investigated.

The Norwegian family belongs to a large kindred originating from the district of Trøndelag in central Norway. A total of 28 family members were included in the study, 22 unaffected subjects and six gene carriers. The biochemical findings and linkage analysis have previously been described.<sup>14</sup> Seven subjects selected from a large, well characterised English family were investigated. Three of them were diagnosed as AIP patients and three as unaffected. One family member was a possible gene carrier and treated as being at risk of AIP, though she had equivocal PBGD enzyme activity and had no AIP symptoms.<sup>15</sup> The two Swedish families comprised 11 AIP carriers, 10 unaffected subjects, and two additional cases, for whom the results of the conventional diagnostic procedure were inconclusive.

The diagnosis of AIP was established or excluded by family history, clinical symptoms, and biochemical analyses, including porphobilinogen deaminase activity in erythrocytes and urinary excretion of porphobilinogen and  $\delta$ -aminolaevulinic acid.

### DNA SEQUENCING

Genomic DNA was investigated by single stranded sequencing of exons 1, 3, 4, 5, 8, 9, 10, 12, and 14 in the PBGD gene. Primers for exon amplification were designed 52-86 bases from the exon/intron border (table).

The first PCR amplification was performed in 10 mmol/l Tris-HCl buffer, pH 8.8, containing 50 mmol/l KCl, 1.5 mmol/l MgCl<sub>2</sub>, 0.1% Triton X-100, 150  $\mu$ mol/l of each dNTP, 25 pmol of each primer, 0.4 units of Dynazyme (Finnzymes Oy), and 100 ng template DNA in

Department of Clinical Genetics/Molecular Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden  
G Lundin  
J Hashemi  
M Anvret

Porphyrias Service Sweden, St Görans Hospital, S-112 81 Stockholm, Sweden  
Y Floderus  
S Thunell

Department of Clinical Chemistry, University Hospital, N-7006 Trondheim, Norway  
E Sagen

UNIGEN, Institute of Biotechnology, University of Trondheim, N-7030 Trondheim, Norway  
A Lægred


Department of Clinical Biochemistry, King's College School of Medicine & Dentistry, Bessemer Road, London SE5 9PJ, UK  
W Wassif  
T Peters

Correspondence to: Dr Lundin.

Received 15 May 1995  
Revised version accepted for publication 31 August 1995

### Primers used for exon amplification of the PBGD gene before single stranded sequencing

Exon 1	NEP-123,F Int1,128,R	5'-GTCAGACTGTAGGACGACCT-3' 5'-ACGACTGAGGATGGCAACCT-3'
Exon 3	Int2,F Int3,R	5'-TCCTTTCTTCCAAGCCAGTGA-3' 5'-CCACCCCATCTCCTTCATAC-3'
Exon 4	Int3,F Int4,R	5'-AAAGAGTCTGAGCCGTGGCT-3' 5'-TGTTCTCTCCTCTCGGGGTA-3'
Exon 5	JS39 JS5	5'-CCATCATGAATCGTAGCACAG-3' 5'-TCATTCTTCTCCAGGGCATG-3'
Exon 8	JS109 Int8,R	5'-CCAGTGAGTTGGCCAATCGAGA-3' 5'-CCTGCATCTTCTGGGCACAT-3'
Exon 9	Int8K Int9,R	5'-TGCCAGAAAGATGCAGGGAT-3' 5'-CAGAGCCCTCTAGACCTTGT-3'
Exon 10	Int9,F Phi10	5'-GGGAAAGACAGACTCAGGCA-3' 5'-TGAACGTATATCGCTTTCACAC-3'
Exon 12	Int11,F Int12,R	5'-GTCCCATGCTTTCGGCCATT-3' 5'-ATCTTCCCTGCCACCTTTCC-3'
Exon 14	Int13,F Int14,R	5'-CTTCTGTGCAATCCCAGGT-3' 5'-GGAGGTGGGATTTGGTGAGA-3'



**Figure 1** Cleavage with restriction enzymes to identify two of the mutations in the PBGD gene. The marker (M) is a 100 bp DNA ladder. (A) A 608 bp fragment is PCR amplified and the normal allele is cleaved by *Bst*NI into 381, 82, 75, and 70 bp (lanes 1 and 3). The fragments of 82, 75, and 70 bp could be seen as one band in the gel. The splicing mutation in the first position of intron 3 (Int3 + 1) is abolishing one of the cleavage sites and an additional fragment of 451 bp is visible (lanes 2 and 4). (B) The mutation in exon 8 (Pro<sup>119</sup>) creates a cleavage site for *Xmn*I and a PCR amplified fragment of 765 bp is cleaved into two fragments of 412 and 353 bp (lanes 1 and 2). The alleles from the healthy subject are uncleaved (lane 3).


a final reaction volume of 50  $\mu$ l. The samples were amplified by 35 cycles of one minute at 94°C, 30 seconds at 58°C, and one minute at 72°C, with an initial denaturing step of seven minutes at 94°C and a final extension step of 10 minutes at 72°C.

From the first PCR, 1  $\mu$ l was used as template in a second, asymmetrical PCR amplification. The conditions of the second PCR were identical, except that the amount of primers were 0.5 pmol (limiting primer) and 50 pmol, with concentration of dNTPs of 25  $\mu$ mol/l.

Single stranded DNA was separated from double stranded DNA on a 4% polyacrylamide gel under non-denaturing conditions, and the sequencing was performed with Sequenase DNA sequencing kit (Amersham).

#### RESTRICTION ENZYME CLEAVAGE ASSAY

Restriction enzyme cleavage was used to screen for the mutations in intron 3 (Int3 + 1) and



**Figure 2** Four new mutations were found in the porphobilinogen deaminase gene. (A) C to T mutation in exon 8 changing Pro<sup>119</sup> to Leu. (B) A splicing mutation in the first position of intron 8. (C) A splicing mutation in the first position of intron 3. (D) G to C mutation in exon 12 changing Glu<sup>250</sup> to Ala.

exon 8 (Pro<sup>119</sup>). The splicing mutation Int3 + 1 abolishes a cleavage site for the restriction enzyme *Bst*NI. A 608 bp fragment was amplified and the normal allele was cleaved by *Bst*NI into four fragments of 381, 82, 75, and 70 bp. The mutated allele, on the other hand, created only three fragments of 451, 82, and 75 bp. The fragments were visualised on a 2% NuSieve agarose gel (fig 1A).

The mutation in exon 8 (Pro<sup>119</sup>) created a cleavage site for the restriction enzyme *Xmn*I. After PCR amplification of a 765 bp fragment, the mutated allele was cleaved into two fragments of 412 and 353 bp. These fragments were separated on a 1% agarose gel (fig 1B).

#### Results

Four new mutations have been found in the PBGD gene in one Norwegian, one English, and two Swedish families with AIP, hitherto uninvestigated (fig 2).

#### PRO<sup>119</sup>

In a large Swedish family, a C-T substitution in exon 8 (position 356) changing Pro<sup>119</sup> to Leu was found (fig 2A). This mutation alters a cleavage site for the restriction enzyme *Xmn*I and can thus easily be detected (fig 1B). It was found in six AIP patients and one possible carrier, diagnosed by conventional clinical and biochemical methods. Six members of the family, in whom the diagnosis of AIP had been rejected, did not carry the mutation. In addition, DNA from 21 normal Swedish controls were screened for this mutation and were shown to be negative.

#### SPLICING MUTATIONS

Two splicing mutations were detected, one at the exon 3/intron 3 border and the other at the exon 8/intron 8 border. The mutation found in the first position of intron 8 (Int8 + 1), a G to T substitution, was found in a large English family (fig 2B). One of the members of this family had an uncertain AIP diagnosis, and carrier status could now be established.

The other splicing mutation, a G to A substitution in the first position of intron 3 (Int3 + 1), was found in a Swedish family with five AIP patients, one inconclusive, and four unaffected family members (fig 2C). This mutation can be detected by cleavage with the restriction enzyme *Bst*NI (fig 1A).

#### GLU<sup>250</sup>

In a large Norwegian family with six AIP patients and 22 unaffected family members, a mutation was found in exon 12. This G to C substitution in position 748 converts Glu<sup>250</sup> to Ala (fig 2D). A mutation in this position has previously been reported in two unrelated families.<sup>6</sup> In these families, however, the substitution was G to A, changing glutamine to lysine. The mutation was confirmed by allele

specific oligonucleotide hybridisation (DOT blot) with the sequence of the mutated allele as probe (data not shown).

### Discussion

Many mutations associated with AIP have been detected in the PBGD gene, including deletions, insertions, missense, nonsense, and splicing mutations. The mutations are scattered throughout the gene, but nearly half of them are found in exons 10 and 12. Only exons 2 and 13 have no reported mutations. In this paper, we present four new mutations in the PBGD gene. Two of these are splicing mutations in the first position of an intron (Int3 + 1 and Int8 + 1), and the other two are missense mutations affecting a single amino acid (Pro<sup>119</sup> and Glu<sup>250</sup>). In exon 8, only two mutations were previously reported, altering the same amino acid (Arg<sup>116</sup>) to tryptophan or glutamine<sup>7,9,10,13</sup>; the mutation we have found affecting Pro<sup>119</sup> is close to this site. The amino acids coded for by exon 8 are situated close to the active site of the enzyme, connecting domains 1 and 2.<sup>16</sup> Changes in this part are likely to impair enzyme activity.

Fifteen base changes have been detected in exon 12 associated with AIP, 10 of them located between codons Leu<sup>245</sup> and Leu<sup>257</sup> in the last third of the exon.<sup>2,4,6,9,10,17-19</sup> Consequently the mutation that changes Glu<sup>250</sup> to Ala is within one of the hot spot regions for PBGD mutations.

The splicing mutations Int3 + 1 and Int8 + 1 both affect the splice donor site, which probably results in defective splicing.

It is of great benefit to AIP families when the actual mutation in the family is detected. This will not only identify family members with latent porphyria, but unaffected members can also be distinguished with confidence.<sup>20</sup> Definitive assignment of AIP status makes it unnecessary for previously equivocal carriers to follow restrictions to prevent AIP attacks and avoids the need for family screening of future generations. In this study we have established carrier status in three subjects where the biochemical analyses were equivocal. In addition to mutations in the PBGD gene itself, there is a possibility of alterations in the regulation of enzyme activity being responsible for the disease and, in that case, the gene promoter regions should also be investigated.

This work was supported by grants from the Swedish Medical Research Council No 9108 (MA), and Torsten and Ragnar Söderberg Foundation (MA).

- Lundin G, Wedell A, Thunell S, *et al.* Two new mutations in the porphobilinogen deaminase gene and a screening method using PCR amplification of specific alleles. *Hum Genet* 1994;93:59-62.
- Mgone CS, Lanyon WG, Moore MR, *et al.* Detection of a high mutation frequency in exon 12 of the porphobilinogen deaminase gene in patients with acute intermittent porphyria. *Hum Genet* 1993;92:619-22.
- Gu X-F, de Rooij F, de Baar E, *et al.* Two novel mutations of the porphobilinogen deaminase gene in acute intermittent porphyria. *Hum Mol Genet* 1993;2:1735-6.
- Daimon M, Yamatani K, Igarashi M, *et al.* Acute intermittent porphyria caused by a G to C mutation in exon 12 of the porphobilinogen deaminase gene that results in exon skipping. *Hum Genet* 1993;92:549-53.
- Llewellyn DH, Whatley S, Elder GH. Acute intermittent porphyria caused by an arginine to histidine substitution (R26H) in the cofactor-binding cleft of porphobilinogen deaminase. *Hum Mol Genet* 1993;2:1315-16.
- Gu X-F, de Rooij F, Voortman G, *et al.* Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis. *Hum Genet* 1994;93:47-52.
- Mgone CS, Lanyon WG, Moore MR, *et al.* Identification of five novel mutations in the porphobilinogen deaminase gene. *Hum Mol Genet* 1994;3:809-11.
- Daimon M, Yamatani K, Igarashi M, *et al.* Acute intermittent porphyria caused by a single base insertion of C in exon 15 of the porphobilinogen deaminase gene that results in a frame shift and premature stopping of translation. *Hum Genet* 1994;93:533-7.
- Chen CH, Astrin KH, Lee G, *et al.* Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. *J Clin Invest* 1994;94:1927-37.
- Kauppinen R, Mustajoki S, Pihlaja H, *et al.* Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene. *Hum Mol Genet* 1995;4:215-22.
- Kappas A, Sassa S, Galbraith RA, *et al.* The porphyrias. In: Scriver CL, ed. *The metabolic basis of inherited disease*. New York: McGraw-Hill, 1989:1305-65.
- Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. *Proc Natl Acad Sci USA* 1991;88:10912-15.
- Lee JS. *Molecular genetic investigation of the human porphobilinogen deaminase gene in acute intermittent porphyria*. Stockholm: Reproprint AB, 1991:1-50.
- Sagen E, Lægread A, Anvret M, *et al.* Genetic carrier detection in Norwegian families with acute intermittent porphyria. *Scand J Lab Invest* 1993;53:687-91.
- Wassif WS, Deacon AC, Floderus Y, *et al.* Acute intermittent porphyria: diagnostic conundrums. *Eur J Clin Chem Clin Biochem* 1994;32:915-21.
- Brownlie PD, Lambert R, Louie GV, *et al.* The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria. *Protein Sci* 1994;3:1644-50.
- Grandchamp B, Picat C, de Rooij F, *et al.* A point mutation G-A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria. *Nucleic Acids Res* 1989;17:6637-49.
- Delfau MH, Picat C, de Rooij F, *et al.* Molecular heterogeneity of acute intermittent porphyria: identification of four additional mutations resulting in the CRIM-negative subtype of the disease. *Am J Hum Genet* 1991;49:421-8.
- Mgone CS, Lanyon WG, Moore MR, *et al.* Detection of seven point mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria, by direct sequencing of in vitro amplified cDNA. *Hum Genet* 1992;90:12-16.
- Andersson C, Thunell S, Floderus Y, *et al.* Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. *J Intern Med* 1995;237:301-8.